Filing summary
Entity note: The supplied filing is Skyline Medical Inc.’s Form 10-Q, not a filing identified as Axe Compute Inc. The summary below reflects the filing’s named registrant. It covers the quarter and six months ended June 30, 2014; financial statements are unaudited.
Business context
Skyline describes itself as a development-stage medical-device company selling the STREAMWAY system for collecting and disposing of surgical fluids, along with related cleaning fluid and filter kits. It began selling an enhanced system in early 2014. The company reported 20 system sales through June 30, 2014, trials and demonstrations at two hospital systems, and purchase orders for approximately 17 systems expected to be installed over the following six months.
Financial performance and liquidity
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $318,293 | $150,856 | $388,513 | $278,583 |
| Gross profit | $219,928 | $83,521 | $259,065 | $169,644 |
| Net loss | $(1,735,954) | $(1,175,535) | $(3,352,949) | $(3,277,061) |
| Loss per share, basic and diluted | $(0.01) | $(0.01) | $(0.02) | $(0.03) |
- Revenue increased approximately 111% for Q2 and 39% for the six-month period year over year. Six-month gross margin was approximately 67%, versus 61% in 2013; management attributed expected future margin improvement to more consistent production and volume purchasing discounts.
- Q2 net loss widened by about $560,000, while the six-month loss widened by about $76,000. For six months, general and administrative expense declined about $202,000, but operations and sales and marketing expenses increased about $147,000 and $329,000, respectively. Interest expense fell about $189,000.
- Cash used in operating activities was $1.95 million for the first six months, compared with $2.12 million in 2013. Investing activities used $87,000; financing activities provided $1.97 million, primarily from the February preferred-stock financing.
- Cash was $40,151 at June 30. Current assets were $699,977 against current liabilities of $3.91 million, implying a working-capital deficit of approximately $3.21 million. Total liabilities were $4.20 million, total assets $972,772, and stockholders’ deficit $3.22 million. The balance sheet included an $81,124 short-term note payable.
- At June 30, 222.9 million common shares were outstanding; the filing reports 223.0 million as of August 4. Options and warrants outstanding at quarter-end totaled approximately 63.6 million, before considering potential conversions of securities issued subsequently.
Outlook, financing, risks and unusual items
- Management forecast operating expenses of about $350,000 per month and said available cash was expected to last approximately through September 30, 2014, after which additional financing would be needed. It stated that product sales could help but cash collections might lag. No formal revenue or earnings guidance was provided.
- The company disclosed substantial doubt about its ability to continue as a going concern, recurring losses, a history of insufficient revenue to fund capital needs, and dependence on further financing. Management warned that financing could be highly dilutive or contain onerous terms, and that failure to raise funds could force reduced or suspended operations, bankruptcy, or closure.
- After quarter-end, on July 23, the company sold convertible notes and warrants for $600,000 in aggregate purchase price—$500,000 from an institutional investor and $100,000 from affiliate SOK Partners—with approximately 22.2% original issue discounts. The notes carry 12% interest and conversion terms linked to market prices; further affiliate financing of up to $900,000 was contemplated but not assured. Management reported approximately $75,000 of operating cash after the initial July funding and expected further tranches.
- On July 17, the company settled a lawsuit related to prior consulting, manufacturing and supply agreements. It agreed to pay $500,000 through April 2015, including $200,000 during the remainder of 2014. Payments may accelerate upon specified financing milestones. The settlement extinguished asserted royalty claims and confirmed the company’s rights to relevant STREAMWAY patents. Management cited the settlement in explaining higher Q2 G&A expense; investors should verify its timing and accounting treatment.
- The February 2014 preferred-stock financing raised $2.055 million. The preferred shares have a $2.055 million stated value and a 1.2-times liquidation preference, plus declared unpaid dividends; they also have conversion and anti-dilution provisions. The company issued additional warrants after failing to meet a specified exchange-listing condition.
- Management reported disclosure controls and procedures were effective at June 30 and no material changes to internal control over financial reporting during the six-month period. It reported no defaults upon senior securities and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Whether the expected financing tranches closed, the company’s subsequent cash balance, and its ability to meet near-term obligations.
- Whether the 17 system orders were installed and converted into billable sales, and whether the two hospital trials led to repeat or larger orders.
- The settlement’s recorded expense and liability, remaining payment schedule, and any acceleration triggered by later financing.
- The dilution and potential repayment exposure from variable-price convertible notes, warrants, preferred-stock rights, and additional contemplated financing.
- The filing’s identity: the document names Skyline Medical Inc., whereas the request metadata names Axe Compute Inc.